{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-019889","form_type":"8-K","ticker":"IMDX","cik":"0001642380","company_name":"Insight Molecular Diagnostics Inc.","filed_at":"2024-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.391039+00:00","generated_at":"2026-06-01T23:14:45.594922+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Oncocyte Q1 revenue down 41% to $176K; operating loss $9.3M; Bio-Rad partnership","bullets":["Net revenue $176K, down 41% YoY; operating loss $9.3M (incl. $3.3M contingent consideration loss) vs income $5.9M in Q1 2023.","Cash burn reduced to $3.9M in Q1; management targets average quarterly burn below $5M.","Announced global commercialization partnership with Bio-Rad; Bio-Rad also bought 8.99% stake via $15.8M equity private placement.","On track to ship RUO GraftAssure kits to initial customers in Asia, US, and EU during Q2 2024; IVD kit under development for FDA."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-019889","json":"https://secwatch.observer/filing/0001493152-24-019889.json","markdown":"https://secwatch.observer/filing/0001493152-24-019889.md","text":"https://secwatch.observer/filing/0001493152-24-019889.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1642380/000149315224019889/0001493152-24-019889-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1642380/000149315224019889/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T23:14:45.594922+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4daba0af2e9b816e9bdca59f61ade34be116c409","claim":"Insight Molecular Diagnostics Inc. reported the quarter ended March 31, 2024 results: revenue $176,000.","evidence_excerpt":"Net revenue for the three months ended March 31, 2024 was $176,000, a decrease of 41% compared to the same period in 2023, due to decreased revenue from our Pharma Services business.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1642380/000149315224019889/0001493152-24-019889-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Revenue","value":"$176,000"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}